Background/Aims: α-mangostin has anti-carcinogenic effects against several cancers. We investigated the molecular mechanism of this compound on the metastasis of human renal carcinoma cells. Methods: Cell viability was measured using the MTT assay, and cell cycle distribution using flow cytometry. A Matrigel-based assay was used to measure in vitro cell migration and invasion. MAPK-related proteins and matrix metalloproteinase (MMP)-9 and MMP-2 expression were measured by western blotting, and MMP2/-9 activities were determined by gelatin zymography. RT-qPCR and a luciferase assay were used to examine the transcriptional activity of MMP-9. Results: α-mangostin inhibited the migration and invasion of RCC cells in a dose-dependent manner, but had no evident cytotoxic effects. Treatment of 786-O cells with α-mangostin inhibited activation of MEK and ERK. Treatment with a specific MEK inhibitor (U0126) enhanced the inhibitory effects of α-mangostin on cell migration and invasion, and the phosphorylation of ERK and MEK. Moreover, α-mangostin inhibited the expression of the MMP-9 mRNA levels as well as the activity of MMP-9 promoter, and these suppressive effects were further enhanced by U0126. Conclusions: Our results suggest that α-mangostin suppresses cell migration and invasion via MEK/ERK/MMP9 pathway, and might be a promising anti-metastatic agent against human renal cell carcinoma.
Introduction
Renal cell carcinoma (RCC) is the most lethal genitourinary cancer, and patients with metastatic RCC have poor overall survival times [1] . Although patients who have RCC but no evidence of metastasis may be treated locally with partial or radical nephrectomy, those with metastatic RCC require cytoreductive nephrectomy followed by newly developed methods, including immunotherapy, anti-angiogenic agents, and mTOR inhibitors, to improve survival time [2] . However, these therapies have limited efficacy when RCC is diagnosed at an advanced stage or if there are distant metastases, because of tumor resistance to chemotherapy, radiotherapy, and hormone therapy [3, 4] . Despite recent encouraging reports that targeted therapy with inhibitors of tyrosine kinase and mTOR can reduce mortality, the prognosis for patients with advanced stage or distant metastases remains dismal [5] .
Chemoprevention of cancer by usage of dietary bioactive compounds could potentially reverse, suppress, or prevent cancer progression [6] . We recently found that nimbolide, a tetranortriterpenoid isolated from the leaves and flowers of the neem tree (Azadirachta indica), can inhibit the growth of RCC [7] . α-mangostin (Fig. 1A) , a natural xanthone isolated from the pericarps of mangosteen (Garcinia mangostma L), known as the "queen of fruits", also has in vitro and in vivo activities against various human malignant cells, in addition to well-known anti-inflammatory, anti-oxidant, and anti-bacterial effects [8, 9] . α-mangostin appears to exert its anti-tumor effects by distinct mechanisms in different types of cancer cells; it induces cell cycle arrest and increases the levels of reactive oxygen species in breast cancer cells [10] , it induces apoptosis in prostate cancer cells [11] , and it inhibits proliferation and promotes apoptosis in gastric cancer cells [12] .
One of the primary reasons for the failure of RCC treatments is that patients with advanced RCC often develop resistance to anti-cancer agents [13] . The matrix metalloproteinases (MMPs), crucial proteolytic proteinases that allow malignant cells to access the vasculature, are a family of zinc-dependent endopeptidases with broad substrate specificities for a variety of extracellular matrix (ECM) and basement membrane proteins [14] . Aberrant regulation of the MMPs disrupts normal cellular interactions, and leads to lysis of the ECM and breaching of the basement membrane, thereby allowing malignant cells to migrate and invade distant tissues [15] . Previous studies of RCC indicated that increased expression of MMP-9 and ERK were associated with the severity of RCC, tumor size, TNM stage, invasion, distant metastasis, and cancer-specific survival [15, 16] . Various intracellular upstream signaling cascades, particularly the mitogen activated protein kinase (MAPK) pathways, regulate the production of MMP-2 and MMP-9. The major components of the MAPK pathways, the ERK, JNK, and p38 MAPK pathways, regulate cell migration, invasion, proliferation, survival, and apoptosis following different cellular signals [17, 18] . α-mangostin can modulate tumor migration and invasion by down-regulating MMP-2, MMP-9, and urokinase-type plasminogen activator (μPA) through the αvβ3 integrin receptor and the FAK/ERK/NF-κB signal pathway in lung cancer [19] , by downregulating the JNK-mediated pathway and inhibition of NK-κB and AP-1 binding activity in prostate cancer [20] , and by suppressing the ERK-mediated pathway and reducing AP-1 and NK-κB binding in breast cancer [21] .
It is important to develop new methods to prevent metastasis of RCC. Despite encouraging reports regarding the efficacy of new therapies for RCC, the prognosis of patients with advanced or metastatic RCC remains poor. It is noteworthy that α-mangostin preferentially targets cancer cells, and has limited toxic effects on normal cells. Thus, α-mangostin has potential as a new therapy for RCC that induces few adverse effects. We examined the effect of α-mangostin on highly invasive human RCC cells and the underlying mechanism of its effect on RCC metastasis.
Materials and Methods

Cell culture
CaKi-1, ACHN, and A-498 cells were routinely cultured in MEM medium, 786-O cells were cultured in RPMI medium, and human renal tubule HK-2 cells were cultured in DMEM-F12 medium. Each growth Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry medium was supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin. All cells were grown in a humidified incubator with 5% CO 2 .
Gelatin zymography assay 786-O cells were seeded in 24 well plates and treated with different concentrations of α-mangostin for 24 h. Then, conditioned media were collected to measure MMP-2 and MMP-9 activity. The medium was subjected to SDS-PAGE in an 8% polyacrylamide gel copolymerized with 0.08% gelatin, as previously reported [22] .
MTT assay
The effect of α-mangostin on the viability of human RCC cells was determined using the MTT assay [23] . Cells were seeded in growth medium in 24-well plates for 24 h, treated with different concentration of α-mangostin for 24 and 48 h, and then the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylterazolium bromide (MTT) reagent was added for 4 h. The formazan precipitate was dissolved in 1 mL isopropanol, and absorbance was measured at 570 nm using a microplate reader (Bio-Rad Laboratories, CA).
In vitro migration and invasion assay Cells (2×10 5 cells/well) were plated onto 6 cm culture plates in medium containing 10% FBS, and then pre-treated with α-mangostin (0, 4, 8, or 12 μM) for 24 h. The lower compartment of polyvinylpyrrolidonefree polycarbonate filters (Millipore; 8-mm pore size) was filled with 50 μL of 10% FBS medium. After incubation, the total number of migrated cells was counted following standard procedures. The in vitro invasiveness was investigated in the upper membranes that were precoated with Matrigel (40 μL, BD Biosciences), as previously described [24] . The number of migrated cells was counted using an inverted microscope (Leica, ×200). Three sets of 5 microscopic fields were counted for each sample.
Western blotting 786-O cells were cultured in 6-cm dishes for 24 h, and then pre-treated with α-mangostin (0, 4, 8, or 12 μM) for 24 h. The cells were washed with cold PBS, harvested, and total protein concentration was measured. The proteins were separated electrophoretically using a 10% SDS-polyacrylamide gel, and then transferred onto an Immobilon P PVDF membrane (Merck Millipore, Billerica, MA). The membranes were blocked in 5% milk for 1 h, and then incubated with primary antibodies for MMP-2, MMP-9, p-MEK, p-ERK, p-p38, p-JNK, MEK, ERK, p38, JNK, and β-actin (loading control) at 4°C overnight. After hybridization with an HRP-conjugated secondary antibody (Santa Cruz Technology), protein bands were visualized using a chemiluminescence detection kit (GE Healthcare, London, UK). The bands were visualized by enhanced chemiluminescence using a Luminescent Image Analyzer LAS-4000 mini (GE Healthcare).
RT-qPCR assay
Total RNA was extracted from α-mangostin-treated cells using a High Pure RNA Tissue Kit (Roche Applied Science, Mannheim, Germany). Total RNA (1 µg) was synthesized by reverse-transcribing total RNA using a ReverTra Ace qPCR RT Master Mix kit (TOYOBO, Japan). The qPCR was performed using a GoTaq qPCR Master Mix (Promega, MW, USA). The primers were: β-actin forward, 5'-GCACTCTTCCAGCCTTCCTTCC-3' and reverse, 5'-TCACCTTCACCGTTCCAGTTTTT-3'; MMP-9 forward, 5'-CCTGCCAGTTTCCATTCATC-3' and reverse, 5'-GCCATTCACGTCGTCCTTAT-3' (MISSION BIOTECH, Taipei, Taiwan). The PCR amplification consisted of 40 cycles at 95°C for 5s, and 58°C for 30s after an initial denaturation step at 95°C for 30s. The results were analyzed using a standard curve-based method. The gene expression is expressed relative to endogenous GAPDH, and determination of the difference in threshold cycle (Ct) between treated and untreated cells using the 2 −ΔΔCt method.
MMP-9 luciferase activity assay
Transfection of 786-O cells with MMP-9 promoter-luciferase vectors was performed using Tuberfast transfection reagents for 24 h, and then addition of α-mangostin (4, 8, or 12 µM) for 24 h. Cells were washed with PBS and lysed with 50 μL passive lysis buffer (Promega, Madison, WI, USA). Lysates were transferred to 96-well plates, and the luciferin substrate was added (Promega, Madison, WI). A microplate reader was used to determine luciferase activity and β-gal enzyme activity was measured with a luciferase assay kit following Fig. 1A shows the structure of α-mangostin. We initially used the MTT assay to determine the effect of this compound on cell viability (Fig. 1) . The results show that it had no significant effects on the growth of normal human proximal tubule epithelial (HK-2) cells or on 4 different lines of RCC cells (786-O, A-498, CaKi, and ACHN) at the tested concentrations (0 to 12 µM) and durations (24 and 48 h). In addition, flow cytometry analysis indicates that a 24 h treatment with α-mangostin had no effect on the cell cycle distribution of A-498 and 786-O RCC cells (Fig. 2) . Based on these results, we used α-mangostin concentrations of 2~12 μM for all subsequent experiments.
Results
α-mangostin does not affect cell viability or cell cycle distribution
α-mangostin inhibits in vitro migration and invasion of RCC cells
We treated A-498 and 786-O cells with different concentrations of α-mangostin for 24 h, and then measured in vitro migration and invasion of these cells. The results indicate that α-mangostin significantly inhibited migration and invasion of each cell type in a concentration-dependent manner (Fig. 3) . At a concentration of 12 µM, the percent migration and invasion of each cell type was about 20~30% of that in the controls (0 µM). and 48 h, and cell viability was determined using the MTT assay. Data are presented as means ± SEs of at least 3 independent experiments.* indicates p < 0.05 and ** indicates p < 0.01 compared with the untreated control (0 μM).
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α-mangostin inhibits protein expression and activity of MMP-9 in RCC cells
Next, we performed western blotting and gelatin zymography of 786-O cells to examine the effect of α-mangostin on the protein expression and activity of MMP-9 and MMP-2, which have important roles in tumor cell migration and invasion. The results show that α-mangostin treatment induced large concentration-dependent reductions of MMP-9 protein expression (Fig. 4A ) and enzyme activity (Fig. 4B ), but had no significant effect on MMP-2 expression and activity. 
α-mangostin inhibits cell migration and invasion via MEK/ERK-mediated MMP-9 expression
Next, we examined the signaling pathway(s) through which α-mangostin inhibits MMP-9 expression in 786-O cells. Treatment of 786-O cells with various concentrations of α-mangostin for 24 h indicated that this compound induced significant concentration-dependent decreases in the phosphorylation of MEK and ERK, but had no significant effect of the phosphorylation of JNK and p38 (Fig. 5) . These findings suggest that α-mangostin appears to inactivate MEK/ERK-mediated signaling pathways. 
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We further investigated the effect of α-mangostin on migration and invasion of RCC cells through the MEK/ERK pathway. Thus, we pretreated 786-O cells with 20 μM U0126 (a specific MEK inhibitor) for 2 h, added α-mangostin (8 μM) for 24 h, and then measured cell migration and invasion. The results indicate that treatment with α-mangostin and U0126 led to greater inhibition of cell migration and invasion than either agent alone (Fig. 6A) . Similarly, western blotting indicated that both agents suppressed the phosphorylation of MEK and ERK and expression of MMP-9 more than either agent alone (Fig. 6B) . These results suggest that α-mangostin suppresses MMP-9 expression through inhibition of the MEK/ ERK signaling pathway, and that this pathway plays a key role in the inhibition of RCC cell migration and invasion.
α-mangostin inhibits transcription of MMP-9 via MEK/ERK pathway
We examined whether α-mangostin treatment regulates MMP-9 expression at the transcriptional level by use of quantitative RT-PCR. The results indicate that α-mangostin inhibited the transcription of MMP-9 in 786-O cells (Fig. 7A) , and that co-administration of α-mangostin and U0126 suppressed the expression of MMP-9 greater than either agent alone (Fig. 7B) . We also examined the effect of α-mangostin and U0126 on the MMP-9 promoter by transfection of 786-O cells with MMP-9 promoter-luciferase vectors. The results indicate a significant concentration-dependent attenuation of luciferase fluorescence in cells treated with α-mangostin for 24 h (Fig. 7C) , and that co-administration of α-mangostin and U0126 suppressed the activity of the MMP-9 promoter more than either agent alone (Fig. 7D) . Taken together, our results suggest that α-mangostin treatment represses the MEK/ERK signaling pathway in RCC cells, and this reduces the activity of the MMP-9 promoter, thereby repressing transcription of MMP-9 and inhibiting cell invasion and migration.
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Discussion
Over the past 15 years, treatments for RCC have evolved from traditional surgical nephrectomy with chemotherapy for localized RCC to therapies that target specific signaling pathways, such as the vascular endothelium growth factor (VEGF) pathway, and mTOR inhibitors for patients with metastatic RCC. However, because of the high cost and toxicities associated with many targeted therapies [25] , and because most patients with metastasis have short survival times-even with these treatments-it is essential to identify new drugs to improve the survival times of these patients. The present in vitro study indicates that α-mangostin inhibited the invasion and migration of RCC cells and had no evident cytotoxic effects. Our further analysis indicated that α-mangostin reduced the expression of MMP-9 mRNA and protein, and this inhibited MEK/ERK signaling pathways in these human RCC cells.
The process of metastasis includes alteration of cell adhesion in the ECM and basement membrane, followed by degradation of ECM and basement membrane cells, detachment of cancer cells from the primary site, invasion into blood vessels and establishment of new tumors at distant sites [26] . The MMPs are a family of zinc-dependent endopeptidases that are critical in promotion of cancer cell invasion and metastasis because they digest basement membrane and ECM proteins, such as collagen, laminin, fibronectin, and proteoglycans. Several upstream signaling pathways regulate the MMPs [27] . Overexpression of several MMPs (MMP-1, MMP-2, and MMP-9) in RCC is associated with tumor stage, histological grade, progression, invasion of microvasculature, and distant metastasis [28] . MMP-9 can degrade collagen and increase the bio-availability of pro-angiogenic factors, such as VEGF and transforming growth factor (TGF)-β [29] . Other studies reported that increased Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry phosphorylation of ERK and enhanced expression of MMP-2 or MMP-9 by treatment with gamma-aminobutyric acid (an inhibitory neurotransmitter) or knockdown of hepatocellular carcinoma-related protein (HCRP) increased the invasive activity of RCC cells [30] . Additional evidence indicates that a pyrrole-imidazole polyamide specifically targets binding sites on the MMP-9 promoter, and thereby inhibits the invasion (but not proliferation) of RCC cells [14] . We demonstrated that α-mangostin had inhibitory effects on the MMP-9 transcription activity and protein expression. This inhibitory effect is likely responsible for the suppressive effects of α-mangostin on RCC cell migration and invasion. Several signaling pathways induce MMP-9 expression, particularly the p38 MAPK, JNK, and ERK pathways [31, 32] . α-mangostin inhibits the expression of MMP-2 and MMP-9 via inhibition of JNK phosphorylation, and thereby suppresses the migration and invasion of PC-3 prostate cancer cells [20] , and it also inhibits ERK signaling pathways in HCT-116 colorectal carcinoma cells [33] and pancreatic cancer cells [34] . Similarly, epigallocatechin-3-gallate, a water-soluble flavonoid, reduces the viability, induces apoptosis, and suppresses the invasion and migration of RCC cells by down-regulation of MMP-2 and MMP-9 [35] . Melatonin also has anti-metastatic effects by reducing p65-and p52-DNA-binding and Aktmediated JNK and ERK signaling pathways, which inhibit MMP-9 transcription [36] .
To the best of our knowledge, this is the first study to document the anti-metastatic effect of α-mangostin on human RCC cells. We demonstrated that α-mangostin inhibited RCC cell migration and invasion by decreasing the expression and activity of MMP-9, and that the α-mangostin-induced inhibition of MMP-9 transcription was due to its suppression of the MEK/ERK pathway (Fig. 8) . These findings suggest that α-mangostin has potential as an anti-metastatic agent. Future animal studies and clinical studies of α-mangostin are needed to assess its therapeutic efficacy against RCC. 
